Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MBIO Stock Forecast 2025-2026
$1.25
Current Price
$5.30M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MBIO Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
MBIO Price Momentum
+11.6%
1 Week Change
+0.8%
1 Month Change
-88.1%
1 Year Change
-85.9%
Year-to-Date Change
-98.1%
From 52W High of $65.00
+23.8%
From 52W Low of $1.01
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Mustang Bio (MBIO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MBIO and similar high-potential opportunities.
Latest MBIO Stock Price Targets & Analyst Predictions
MBIO has shown a year-to-date change of -85.9% and a 1-year change of -88.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for MBIO. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MBIO Analyst Ratings
1
Buy
0
Hold
0
Sell
MBIO Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.25
Latest MBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MBIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| May 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $2.00 |
| Aug 24, 2023 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $18.00 |
| Aug 16, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $25.00 |
| Aug 15, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $25.00 |
| Aug 15, 2023 | BTIG | Justin Zelin | Buy | Maintains | $16.00 |
| Jun 16, 2023 | BTIG | Justin Zelin | Buy | Maintains | $20.00 |
| Jun 16, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $25.00 |
| May 15, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $7.00 |
| Mar 30, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $7.00 |
| Nov 16, 2022 | BTIG | Justin Zelin | Buy | Maintains | $4.00 |
| Jan 24, 2022 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $6.00 |
| May 18, 2021 | BTIG | Buy | Initiates | $0.00 | |
| Oct 2, 2020 | B. Riley Securities | Buy | Initiates | $0.00 | |
| Oct 2, 2020 | B. Riley FBR | Buy | Initiates | $0.00 | |
| May 12, 2020 | Oppenheimer | Outperform | Maintains | $13.00 | |
| Aug 13, 2019 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| Aug 13, 2019 | H.C. Wainwright | Buy | Initiates | $0.00 | |
| Jun 21, 2019 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
| Dec 21, 2017 | Oppenheimer | Outperform | Initiates | $0.00 |
Mustang Bio Inc. (MBIO) Competitors
The following stocks are similar to Mustang Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mustang Bio Inc. (MBIO) Financial Data
Mustang Bio Inc. has a market capitalization of $5.30M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +406.7%.
Valuation Metrics
Market Cap
$5.30M
Enterprise Value
$-9,021,374
P/E Ratio
0.0x
PEG Ratio
-3.5x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+260.1%
Current Ratio
1.3x
Debt/Equity
0.0x
ROE
+406.7%
ROA
-32.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Mustang Bio Inc. (MBIO) Business Model
About Mustang Bio Inc.
What They Do
Develops targeted therapies for cancer and genetic diseases.
Business Model
The company generates revenue through the development and commercialization of innovative therapies, particularly focusing on CAR-T cell and gene therapies. Mustang Bio collaborates with academic institutions and research partners to enhance its R&D capabilities, aiming to bring transformative therapies to market that address unmet medical needs.
Additional Information
Mustang Bio operates in the rapidly evolving biotechnology industry, emphasizing the importance of its contributions to patient care. Its robust pipeline and scientific expertise position it as a key player in delivering cutting-edge medical solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
6
CEO
Dr. Manuel Litchman M.D.
Country
United States
IPO Year
2017
Website
www.mustangbio.comMustang Bio Inc. (MBIO) Latest News & Analysis
Latest News
Quick Summary
Mustang Bio, Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement, as notified by Nasdaq. The company trades under the ticker MBIO.
Why It Matters
Mustang Bio's compliance with Nasdaq's equity requirement enhances its financial stability, potentially boosting investor confidence and share price stability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mustang Bio, Inc. has exited its manufacturing lease in Worcester, MA, selling fixed assets to AbbVie for $1 million. The company focuses on cell therapies for difficult cancers.
Why It Matters
Mustang Bio's lease exit and asset divestment indicate a strategic pivot, potentially reducing operational costs and reshaping its focus, impacting future growth and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mustang Bio, Inc. closed a public offering of 2,657,807 shares at $3.01 each, along with Series C-1 and C-2 warrants. The warrants have varying expiration dates post-stockholder approval.
Why It Matters
Mustang Bio's public offering raises capital for growth, impacting stock liquidity and potential dilution. The introduction of warrants adds complexity to future stock valuations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mustang Bio, Inc. (Nasdaq: MBIO) has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange.
Why It Matters
Mustang Bio's compliance with Nasdaq's minimum bid price requirement enhances its credibility and stability, potentially attracting more investors and improving stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mustang Bio, Inc. has priced a public offering of 2,657,807 shares and warrants at $3.01 each. The offering is expected to close on February 7, 2025, pending customary conditions.
Why It Matters
Mustang Bio's public offering indicates a strategy to raise capital, impacting share dilution and funding for ongoing projects. Market reaction may influence stock price and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Mustang Bio Announces Reverse Stock Split
4 months ago
Quick Summary
Mustang Bio, Inc. will implement a 1-for-50 reverse stock split effective January 16, 2025, with shares trading on a split-adjusted basis thereafter.
Why It Matters
A 1-for-50 reverse stock split can signal financial distress, potentially affecting investor perception and stock liquidity, while also impacting share price volatility.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MBIO Stock
What is Mustang Bio Inc.'s (MBIO) stock forecast for 2025?
Analyst forecasts for Mustang Bio Inc. (MBIO) are not currently available. The stock is trading at $1.25.
Is MBIO stock a good investment in 2025?
According to current analyst ratings, MBIO has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MBIO stock?
Price predictions from Wall Street analysts for MBIO are not currently available. The stock is trading at $1.25.
What is Mustang Bio Inc.'s business model?
The company generates revenue through the development and commercialization of innovative therapies, particularly focusing on CAR-T cell and gene therapies. Mustang Bio collaborates with academic institutions and research partners to enhance its R&D capabilities, aiming to bring transformative therapies to market that address unmet medical needs.
What is the highest forecasted price for MBIO Mustang Bio Inc.?
Price targets from Wall Street analysts for MBIO are not currently available. The stock is trading at $1.25.
What is the lowest forecasted price for MBIO Mustang Bio Inc.?
Price targets from Wall Street analysts for MBIO are not currently available. The stock is trading at $1.25.
What is the overall MBIO consensus from analysts for Mustang Bio Inc.?
The overall analyst consensus for MBIO is bullish. Out of 5 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are MBIO stock price projections?
Stock price projections, including those for Mustang Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 24, 2025 3:38 AM UTC